Cleo Diagnostics (ASX:COV) Change In Receivables : A$0.00 Mil (TTM As of Dec. 2023)

View and export this data going back to 2023. Start your Free Trial

What is Cleo Diagnostics Change In Receivables?

Cleo Diagnostics's change in receivables for the quarter that ended in Dec. 2023 was A$0.00 Mil. It means Cleo Diagnostics's Accounts Receivable stayed the same from Jun. 2023 to Dec. 2023 .

Cleo Diagnostics's change in receivables for the fiscal year that ended in Jun. 2023 was A$0.00 Mil. It means Cleo Diagnostics's Accounts Receivable stayed the same from . 20 to Jun. 2023 .

Cleo Diagnostics's Accounts Receivable for the quarter that ended in Dec. 2023 was A$0.16 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Cleo Diagnostics's liquidation value for the six months ended in Dec. 2023 was A$10.03 Mil.

Cleo Diagnostics Change In Receivables Historical Data

The historical data trend for Cleo Diagnostics's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cleo Diagnostics Change In Receivables Chart

Cleo Diagnostics Annual Data

Trend

Jun23

Change In Receivables

Cleo Diagnostics Semi-Annual Data
	Dec22	Jun23	Dec23
Change In Receivables	-	-	-

Cleo Diagnostics Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$0.00 Mil.

Cleo Diagnostics (ASX:COV) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Cleo Diagnostics's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0.162	/	0	*	91
=

2. In Ben Graham's calculation of liquidation value, Cleo Diagnostics's accounts receivable are only considered to be worth 75% of book value:

Cleo Diagnostics's liquidation value for the quarter that ended in Dec. 2023 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	10.108	-	0.199	+	0.75 * 0.162	+	0.5 * 0
=	10.03

Cleo Diagnostics Change In Receivables Related Terms

Thank you for viewing the detailed overview of Cleo Diagnostics's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Cleo Diagnostics (ASX:COV) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Cleo Diagnostics Ltd (ASX:COV) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

480 Collins Street, Level 2, Melbourne, VIC, AUS, 3000

Website

https://www.cleodx.com

Cleo Diagnostics Ltd is focused on the development of non-invasive blood-based IVD tests to detect the presence, and recurrence, of ovarian cancer. The Company's first product to market is intended to be the Triage Test which has to date produced strong results to accurately differentiate patients with malignant ovarian cancer from those with benign gynaecological conditions. The Company aims to improve the diagnostic process and procedures for detecting ovarian cancer and, in this regard, improve quality-of-life outcomes for patients who have been diagnosed with ovarian cancer.

Cleo Diagnostics (ASX:COV) Headlines

No Headlines